What is analysed in first-trimester screening?
First-trimester screening evaluates biochemical and ultrasound markers to detect potential chromosomal abnormalities, such as Down syndrome (trisomy 21) and other trisomies. Specific hormones in the mother’s blood are analysed, and an ultrasound measures the foetal nuchal translucency.
How is it used?
Screening results provide a statistical value indicating the risk of chromosomal abnormalities. These values help guide decisions regarding further tests, such as amniocentesis or chorionic villus sampling.
Why is this analysis performed?
To identify potential chromosomal risks in the foetus and to provide information to parents for informed decision-making.
When should the analysis be carried out?
Ideally, between weeks 11 and 14 of pregnancy. It can be combined with a first-trimester ultrasound.
Is any sample required?
Maternal blood is drawn to analyse specific hormones.
Is any prior preparation required?
No special preparation is required. Patients should inform their doctor of any recent medications or supplements.